A significant drop in Appili Therapeutics Inc's stock raises concerns among investors.
Appili Therapeutics Inc (APLI.TO) experienced a sharp decline yesterday, closing down 33.33% at CA$0.01. This dramatic drop has left investors questioning the company's stability and future prospects.
Investor takeaway: Investors should closely monitor Appili Therapeutics Inc for any developments that could impact its recovery, especially in light of recent operational challenges.
Advertisement
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$1.32M
52W high
$0.04
52W low
$0.01
1W change
+0.00%
Beta
-0.19
Analyst Price Targets
Based on analyst covering APLI · as of Sep 17, 2026
Wall Street analysts forecast APLI stock price to rise 1400.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+1400.0% Upside
Current Price
C$0.01
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
430.4%
Annualized
90-Day Vol
299.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.00 – C$0.04 |
| 60 trading days | C$0.01 | C$0.00 – C$0.07 |
| 90 trading days | C$0.01 | C$0.00 – C$0.11 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Appili Therapeutics Inc's stock fell 33.33% yesterday
The stock's decline reflects significant investor concerns about the company's ongoing projects and operational execution.
Bull case
If Appili can successfully address its operational setbacks and make the most of its recent funding, there could be a chance for recovery and growth in the long run.
Bear case
The termination of the VXV-01 program by NIAID raises serious doubts about the viability of Appili's projects, which could further erode investor confidence.
Market Reaction
Advertisement
The 33.33% drop in Appili's stock price yesterday can be attributed to a combination of investor sentiment and recent operational challenges. The company's announcement about the termination of the VXV-01 program by NIAID has raised red flags, leading to a swift sell-off.
Operational Challenges
Appili's recent financial results showed some progress, but the termination of key programs has overshadowed these achievements. Investors are now left wondering about the company's future direction and its ability to recover from this setback. For more details on their financial performance, check out the Appili Therapeutics stock page.
Looking Ahead
With a market cap of just CA$1.98 million, Appili Therapeutics Inc is at a critical juncture. Investors should keep a close eye on any updates regarding the company's strategic plans and operational adjustments. For ongoing updates, visit the APLI.TO stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
